Compare CRVS & HIFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRVS | HIFS |
|---|---|---|
| Founded | 2014 | 1834 |
| Country | United States | United States |
| Employees | 37 | 97 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 811.8M | 679.7M |
| IPO Year | 2016 | N/A |
| Metric | CRVS | HIFS |
|---|---|---|
| Price | $9.68 | $293.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $33.14 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 29.3K |
| Earning Date | 11-03-2026 | 10-16-2026 |
| Dividend Yield | N/A | ★ 0.86% |
| EPS Growth | ★ 48.04 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.63 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.39 | $249.58 |
| 52 Week High | $26.95 | $338.00 |
| Indicator | CRVS | HIFS |
|---|---|---|
| Relative Strength Index (RSI) | 32.50 | 47.17 |
| Support Level | $6.39 | $278.27 |
| Resistance Level | $13.73 | $290.87 |
| Average True Range (ATR) | 0.58 | 7.89 |
| MACD | -0.04 | 0.62 |
| Stochastic Oscillator | 17.38 | 56.14 |
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Hingham Institution for Savings is a Massachusetts-chartered savings bank headquartered in Hingham, Massachusetts. The bank is principally engaged in the business of commercial and residential real estate mortgage lending, funded by a mix of retail and commercial deposits, wholesale deposits and borrowings. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending products are residential and commercial mortgage loans secured by properties in eastern Massachusetts. The bank also lends to commercial and residential real estate borrowers and services deposits for customers in the greater Washington, D.C. metropolitan area (WMA) and in the San Francisco Bay Area.